Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Clinical trial NCT00559702 · COMPLETED

Trial details

NCT number: NCT00559702
Sponsor: Biogen
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Start date: 2007-10-01
Primary completion: 2011-11-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.